Important information. Laboratory research only · No medical advice.
Status comes first
Retatrutide is an investigational molecule in clinical development. Eli Lilly calls it investigational and the EU register lists ongoing studies. That is not marketing authorisation.
Mechanism is not a promise
Activity at GLP-1, GIP and glucagon receptors describes the research strategy. It does not predict an individual's outcome or establish long-term safety.
Read the study in context
Population, comparator, duration, attrition and adverse events must be read together. A trial product does not establish the identity or quality of another supplier's material.
A clear boundary
SWE Beauty Peptide provides no dosing, injection or treatment information. Enquiries must concern legitimate laboratory research.